Eurofins Central Laboratory is pleased to announce that is has achieved an important strategic milestone with the expansion and relocation of its US Central Laboratory Operations
Eurofins Central Laboratory is pleased to announce that is has achieved an important strategicmilestone with the expansion and relocation of its U.S. Central Laboratory Operations to the330,000 square foot Eurofins Pharma Services campus in Lancaster, PA. The consolidation ofthe Central Laboratory into the Lancaster Laboratories campus, combined with the recentlyannounced acquisitions of leading bioanalytical, discovery, genomic and diagnostic laboratoriesin the US, positions Eurofins as a leading full service laboratory provider to the pharmaceuticaland biotech industries. This purpose built Central Laboratory is essential to the Eurofins CentralLaboratory global footprint of wholly-owned laboratory facilities in the United States, Europe,Asia and China.
Dr. Charles J. DiComo, Vice President & General Manager, U.S. & Global Laboratory Operations, explains: “The Central Laboratory in Lancaster is fully harmonized and seamlessly aligned with our other Eurofins Central Laboratories. All laboratory equipment, analytical methods, standard operating procedures and quality standards are identical across laboratories to support clinical trials being conducted across regions by our clients. Operating in line with both GLP and GCP standards, and with a strong expertise in biomarker analysis, we are positioning ourselves to become the first-choice Central Laboratory for our pharmaceuticalsponsors.”
Successfully operational since early April, the Eurofins Central Laboratory in Lancaster offers a full package of safety and esoteric testing. Furthermore, this location houses the Microbiology Center of Excellence for Eurofins Central Laboratory. The facility is accredited by thePennsylvania Department of Health, CAP, CLIA and NGSP Level I.
Elena Logan, Global Vice President Sales & Marketing, remarks: “The expansion of our Central Laboratory services on the Lancaster campus signifies the importance of this business within the portfolio of offerings of Eurofins Pharma Services. The Central Laboratory is core to the integration of our other laboratory services and as such, we continue to make significant investments in the business to ensure customers receive first class service and optimal delivery of results to support key decision making during and as a result of the clinical trials being run with Eurofins.”
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.